SCHEMBL6319456

SCHEMBL6319456

Cc1cc(C(=O)N2CCC(N3CCCC3)CC2)c(/C=C2\C(=O)Nc3cccc(-c4cc(F)cc(F)c4)c32)[nH]1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 6/20 0.41
PDGFRB P09619 2/20 0.41
KIT P10721 2/20 0.41
L3MBTL1 Q9Y468 6/20 0.39
L3MBTL3 Q96JM7 5/20 0.39
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
PARP1 P09874 1/20 0.39
PARP2 Q9UGN5 1/20 0.39
CDK5 Q00535 1/20 0.38
CDK5R1 Q15078 1/20 0.38
TDP1 Q9NUW8 2/20 0.38
TP53BP1 Q12888 2/20 0.38
SMYD2 Q9NRG4 1/20 0.38
FLT1 P17948 4/20 0.37
ALK Q9UM73 3/20 0.37
CSF1R P07333 2/20 0.37
RET P07949 2/20 0.37
FGFR1 P11362 2/20 0.37
SRC P12931 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6329837 0.95 KDR (0.42) KDRPDGFRBKITL3MBTL1L3MBTL3
SCHEMBL6323517 0.91 L3MBTL3 (0.47) KDRPDGFRBKITL3MBTL1L3MBTL3
SCHEMBL6327802 0.89 KDR (0.43) KDRPDGFRBKITL3MBTL1L3MBTL3
SCHEMBL6322401 0.89 KDR (0.40) KDRPDGFRBKITL3MBTL1L3MBTL3
SCHEMBL6766682 0.87 KDR (0.37) KDRPDGFRBKITL3MBTL1L3MBTL3
SCHEMBL6321738 0.87 TLR9 (0.42) KDRPDGFRBL3MBTL1L3MBTL3CDK5
SCHEMBL6321376 0.86 CYP2D6 (0.40) KDRL3MBTL1L3MBTL3CDK5CDK5R1
SCHEMBL6327898 0.84 KDR (0.38) KDRPDGFRBKITMEN1KMT2A
SCHEMBL6327922 0.83 ALK (0.40) KDRPDGFRBKITMEN1KMT2A
SCHEMBL6322518 0.83 FLT1 (0.41) KDRPDGFRBKITMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6861418-B2 4-aryl substituted indolinones SUGEN, INC. (US) 2005-03-01 US disclosed
US-20040157909-A1 4-Aryl substituted indolinones SUGEN, INC. 2004-08-12 US disclosed
US-6677368-B2 4-aryl substituted indolinones SUGEN, INC. 2004-01-13 US disclosed
US-20030069297-A1 4-aryl substituted indolinones SUGEN, INC. 2003-04-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069297-A1 4-aryl substituted indolinones CDK5, CAMK4, TNK2 KDR 819/4885PDGFRB 575/4885KIT 972/4885
US-20040157909-A1 4-Aryl substituted indolinones CDK5, CAMK4, TNK2 KDR 819/4885PDGFRB 575/4885KIT 972/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.